Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Current Assets (2016 - 2026)

Usana Health Sciences has reported Current Assets over the past 16 years, most recently at $294.2 million for Q2 2026.

  • Quarterly Current Assets rose 4.56% to $294.2 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $294.2 million through Apr 2026, up 4.56% year-over-year, with the annual reading at $288.4 million for FY2026, 3.3% up from the prior year.
  • Current Assets was $294.2 million for Q2 2026 at Usana Health Sciences, up from $288.4 million in the prior quarter.
  • Over five years, Current Assets peaked at $451.2 million in Q3 2024 and troughed at $261.9 million in Q2 2025.
  • The 5-year median for Current Assets is $364.5 million (2022), against an average of $352.7 million.
  • Year-over-year, Current Assets increased 15.55% in 2024 and then plummeted 41.47% in 2025.
  • A 5-year view of Current Assets shows it stood at $384.4 million in 2022, then grew by 8.68% to $417.7 million in 2023, then tumbled by 33.17% to $279.2 million in 2024, then fell by 5.42% to $264.1 million in 2025, then rose by 11.42% to $294.2 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Current Assets are $294.2 million (Q2 2026), $288.4 million (Q1 2026), and $264.1 million (Q3 2025).